Literature DB >> 12644265

Molecular cloning and functional characterization of the OCTN2 transporter at the RBE4 cells, an in vitro model of the blood-brain barrier.

Anne Friedrich1, Puttur D Prasad, Dorette Freyer, Vadivel Ganapathy, Peter Brust.   

Abstract

The transport of L-carnitine (4-N-trimethylamino-3-hydroxybutyric acid), a compound known to be transported by the organic cation transporter/carnitine transporter OCTN2, was studied in immortalized rat brain endothelial cells (RBE4). The cells were found to take up L-carnitine by a sodium-dependent process. This uptake process was saturable with an apparent Michaelis-Menten constant for L-carnitine of 54+/-10 microM and a maximal velocity of 215+/-35 pmol/mg protein/h. Besides L-carnitine, the cells also took up acetyl-L-carnitine and propionyl-L-carnitine in a sodium-dependent manner and TEA in a sodium-independent manner. RT-PCR with primers specific for the rat OCTN2 transporter revealed the existence of OCTN2 mRNA in RBE4 cells. Screening of a cDNA library from RBE4 cells with rat OCTN2 cDNA as a probe identified a positive clone which showed, when expressed in HeLa cells, the functional characteristics of OCTN2. The HeLa cells expressing the RBE4 OCTN2 cDNA showed a sixfold increase in L-carnitine uptake and a fourfold increase in TEA uptake in a sodium-containing buffer. Typical inhibitors for organic cation transporters (e.g. MPP(+) or TEA) showed an inhibitory effect on the transport of L-carnitine and TEA into the transfected cells. Similarly, unlabeled L-carnitine inhibited the transport of [3H]-L-carnitine and [14C]TEA in transfected HeLa cells. It is concluded that RBE4 cells, a widely used in vitro model of the blood-brain barrier (BBB), express the organic cation/carnitine transporter OCTN2.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12644265     DOI: 10.1016/s0006-8993(02)04271-3

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  8 in total

1.  Molecular and functional characterization of riboflavin specific transport system in rat brain capillary endothelial cells.

Authors:  Mitesh Patel; Ramya Krishna Vadlapatla; Dhananjay Pal; Ashim K Mitra
Journal:  Brain Res       Date:  2012-06-07       Impact factor: 3.252

Review 2.  Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems.

Authors:  Akira Tsuji
Journal:  NeuroRx       Date:  2005-01

Review 3.  Rat brain endothelial cell lines for the study of blood-brain barrier permeability and transport functions.

Authors:  Françoise Roux; Pierre-Olivier Couraud
Journal:  Cell Mol Neurobiol       Date:  2005-02       Impact factor: 5.046

Review 4.  Solute Carriers in the Blood-Brain Barier: Safety in Abundance.

Authors:  Katarzyna A Nałęcz
Journal:  Neurochem Res       Date:  2016-08-09       Impact factor: 3.996

5.  The acetylcholinesterase inhibitors competitively inhibited an acetyl L-carnitine transport through the blood-brain barrier.

Authors:  Na-Young Lee; Hyung-Ok Choi; Young-Sook Kang
Journal:  Neurochem Res       Date:  2012-02-23       Impact factor: 3.996

6.  Uptake and efflux of quinacrine, a candidate for the treatment of prion diseases, at the blood-brain barrier.

Authors:  Shinya Dohgu; Atsushi Yamauchi; Fuyuko Takata; Yasufumi Sawada; Shun Higuchi; Mikihiko Naito; Takashi Tsuruo; Susumu Shirabe; Masami Niwa; Shigeru Katamine; Yasufumi Kataoka
Journal:  Cell Mol Neurobiol       Date:  2004-04       Impact factor: 5.046

Review 7.  The blood-brain barrier and methamphetamine: open sesame?

Authors:  Patric Turowski; Bridget-Ann Kenny
Journal:  Front Neurosci       Date:  2015-05-05       Impact factor: 4.677

8.  Oxaliplatin-induced blood brain barrier loosening: a new point of view on chemotherapy-induced neurotoxicity.

Authors:  Lorenzo Di Cesare Mannelli; Alessandra Pacini; Jacopo Junio Valerio Branca; Mario Maresca; Gabriele Morucci; Matteo Becatti; Ferdinando Paternostro; Massimo Gulisano; Carla Ghelardini; Daniela Salvemini
Journal:  Oncotarget       Date:  2018-05-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.